abstract |
The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binders, in particular as 5-HT1A receptor antagonists and agonists. Such compounds are useful for treating central nervous system disorders such as cognitive disorders, anxiety disorders, depression and sexual dysfunction. |